Drug intelligence / Profile preview

Nobivac Rabies

Development stage
Unknown
Lead developer
Intervet
Modality
Vaccines & Immunotherapeutics
Administration
Subcutaneous, Intramuscular
01

Overview

**Nobivac Rabies** is an inactivated, adjuvanted veterinary vaccine containing rabies virus strain Pasteur RIV (≥2 mouse potency IU per dose, adjuvanted with aluminum phosphate) designed for active immunization of dogs, cats, ferrets, cattle, and sheep against rabies infection. It induces a protective serological response (≥0.5 IU) within 2-3 weeks post-vaccination, with a proven duration of immunity of 3 years in dogs and cats (1 year in some formulations or species like cattle/sheep). Administered as a single 1 mL dose subcutaneously or intramuscularly starting at 12 weeks of age (earlier with revaccination at 12 weeks), it is produced by MSD Animal Health (Merck Animal Health in some regions) on an established cell line, is safe in pregnant dogs based on field data, contains preservatives like gentamicin and thiomersal, and can be mixed with select Nobivac core vaccines but not leptospirosis vaccines.[1][2][3][4]

Brand names
Nobivac Rabies
02

Targets

RABV-G (Rabies virus glycoprotein)

Beyond the preview

Go deeper on Nobivac Rabies.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nobivac Rabies.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call